TA1 vs Vilon
A side-by-side research comparison of TA1 and Vilon across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | TA1 | Vilon |
|---|---|---|
| Full name | Thymosin Alpha-1 (TA1 - Clinical Form) | Vilon (Lys-Glu Dipeptide Immune Bioregulator) |
| Category | Immune Support | Immune Support |
| Status | Approved internationally (not FDA-approved) | Research compound (peptide bioregulator) |
| Mechanism | Activates TLR2/9 on dendritic cells, promotes T-cell differentiation, and enhances cytokine-mediated immune signaling cascades. | As a very short signal peptide (Lys-Glu), it is proposed to bind DNA and modulate gene expression in immune and other tissues, influencing chromatin activity, cytokine balance, and cellular aging markers. |
| Molecular weight | 3108.3 Da | ~275 Da |
| Half-life | ~2-3 hours | Short (peptide) |
| Bioavailability | ~85% subcutaneous | Oral (encapsulated) or subcutaneous |
| Typical dose | 1.6 mg | ~1-2 capsules/day or short injectable courses |
| Frequency | 2x per week | Once daily |
| Route | Subcutaneous injection | Oral capsule or subcutaneous |
TA1 reported benefits
- Standardized immune enhancement
- Proven antiviral adjunct
- Cancer immunotherapy support
- Vaccine response enhancement
Vilon reported benefits
- Immune regulation support
- Gene-expression modulation (proposed)
- Anti-aging tissue effects (proposed)
- Short course-based protocol
Related comparisons
Research and educational reference only. Not medical advice.